FILE PHOTO: Doctor Oezge Kaya delivers the first dose of the Pfizer-BioNTech vaccine against the coronavirus disease (COVID-19) to a woman at a doctor's practice in Berlin, Germany, April 13, 2021. REUTERS/Alessia Cocca
BERLIN (Reuters) - The main challenge to raising production of COVID-19 vaccines is how to quickly and effectively transfer technology, Germany's health minister said Friday, reiterating Berlin's opposition to a U.S. proposal to waive patent protection.
"The main issue is not patent protection but production capacity," Jens Spahn told a news conference on Friday.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
